当前位置：首页 > 文献互助 > 互助详情

Efficacy and Safety of BI 1358894 in Patients With Borderline Personality Disorder复制

定风波 1个月前 84 10 已完结

1. 系统已在2026-02-11 11:36:26对应助文件进行删除

2. 如有需要请重新发布求助信息

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.4088/jcp.24m15523复制

文献链接: https://www.psychiatrist.com/jcp/efficacy-safety-bi-1358894-borderline-personality-disorder-phase-2-trial/复制

其他信息:

出版社: Physicians Postgraduate Press, Inc
作者: Jennifer B. Dwyer; Christian Schmahl; Manabu Makinodan; Sarah K. Fineberg; Stephanie Sommer; Jan Wruck; Ante Jelaska; Abidemi Adeniji; Marianne Goodman

上一篇：Efficacy, Tolerability, and Safety of TRPC4/5 Inhibitor BI 1358894 in Patients With Major Depressive Disorder and Inadequate Response to Antidepressants

下一篇：Toward More Trustworthy QSAR: A Systematic Discussion on Data Set Partitioning

互助时间线

2026-02-09 09:38:58 [完结求助]

系统完结了求助, 已自动确认了实证研究应助的文件是正确的, 求助状态变成 已完结

2026-02-04 11:36:26 [上传文件]

实证研究上传了文件(pdf 5.29 MB), 求助状态变成 待确认

2026-02-04 09:38:58 [发起求助]

最新发布的求助

Regenerable liquid metal nanozymes enable pH-regulated multi-enzyme mimicking 39分钟前
Regenerable liquid metal nanozymes enable pH-regulated multi-enzyme mimicking 45分钟前
Upcycling of Acid Waste Gases Using Asymmetric Atomic-Copper-Anchored Covalent Organic Framework Catalyst 48分钟前
All-perovskite tandem 1 cm² cells with improved interface quality 50分钟前
Physiologic disruption and metabolic reprogramming in infection and sepsis 55分钟前
World Health Assembly Resolution Strengthening Medical Imaging Capacity: Impact on Medical Imaging Globally 59分钟前
A patent review of CHK1 inhibitors (2019 - present) 1小时前
Photonic neural networks for in-memory and in-sensor computing for AI processors 2小时前
Emerging muscarinic receptor antagonists for the treatment of asthma哮喘治疗中新兴的毒蕈碱受体拮抗剂 2小时前
Long-acting muscarinic receptor antagonists for the treatment of respiratory disease长效毒蕈碱受体拮抗剂用于治疗呼吸道疾病 2小时前
The Mitochondrial Blueprint of Skin Aging: From Damage Signals to Dermatologic Interventions 2小时前
Messages in a vesicle: exosomes at the crossroads of skin pathology and healing 2小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com